1. Auflage - August 2008
139,- Euro
2008. 1064 Seiten, Hardcover
- Monographie -
ISBN-10: 0-470-10884-3
ISBN-13: 978-0-470-10884-0 - John Wiley & Sons

Preis inkl. Mehrwertsteuer zzgl. Versandkosten.





Probekapitel

Kurzbeschreibung
Proper preclinical safety evaluation can lessen the time and cost of launching new biopharmaceuticals and speed potentially life-saving drugs to market. This guide covers everything from lead candidate selection to establishing proof of concept and toxicity testing to the selection of the first human doses. With chapters contributed by experts in their specific areas, Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials:

* Includes an overview of biopharmaceuticals with information on regulation and methods of production
* Discusses the principles of ICH S6 and their implementation in the U.S., Europe, and Japan
* Covers current practices in preclinical development and includes a comparison of safety assessments for small molecules with those for biopharmaceuticals
* Addresses all aspects of the preclinical evaluation process, including: the selection of relevant species; safety/toxicity endpoints; specific considerations based upon class; and practical considerations in the design, implementation, and analysis of biopharmaceuticals
* Covers transitioning from preclinical development to clinical trials

This is a hands-on, straightforward reference for professionals involved in preclinical drug development, including scientists, toxicologists, project managers, consultants, and regulatory personnel.

Aus dem Inhalt
Foreword.

Acknowledgments.

Contributors.

Part I: Background.

Part II: Principles of Preclinical Development.

Part III: Current Practices in Preclinical Development.

Part IV: Selection of Relevant Species.

Part V: Safety/Toxicity Endpoints.

Part VI: Specific Considerations Based on Product Class.

Part VII: Preclinical Study Design, Implementation, and Analysis.

Part VIII: Transitioning From Preclinical Development to Clinical Trials.

Part IX: Afterword.

Index.